Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officer646-378-2923650-934-5200
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Corporation (NASDAQ: LIFE ) today announced that ... open-access resource for Ion Torrent users and developers, has ... sudden jump in membership began after Ion Torrent published ... Ion Personal Genome Machine™ (PGM™), the world,s first benchtop ...
... 2011 BioNeutral Group, Inc. (OTCBB: BONU), a ... it has received $400,000 in connection with the ... Pty Ltd ("Vinfluence"), New South Wales, Australia.  Pursuant ... from the initial closing and a second funding ...
... computer assisted design (CAD) tools that made it ... transistors may soon be coming to the biological ... (DOE),s Joint BioEnergy Institute (JBEI) have developed CAD-type ... it possible to engineer biological components or "RNA ...
Cached Biology Technology:Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 2Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 3Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 4Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 5BioNeutral Group Receives $400,000 in Equity Financing 2BioNeutral Group Receives $400,000 in Equity Financing 3CAD for RNA 2CAD for RNA 3CAD for RNA 4
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
(Date:4/17/2014)... The White House honored Clemson professor Rajendra Singh ... efforts to promote and expand solar deployment in ... the D. Houser Banks Professor of Electrical and ... Silicon Nanoelectronics, is considered a local hero leading ... and economic opportunity in solar power and driving ...
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... and Imperial College London today signed an official agreement ... was previously announced by Prime Minister Lee Hsien Loong ... the working name for the school is "Imperial College ... start in 2013, ICNMS will be positioned to meet ...
... Department of Energy,s Joint BioEnergy Institute (JBEI) have ... the development of a next generation of clean, ... economics and well as performance. This on-line, wiki-based ... strategies for cost-efficient biorefinery operations by simulating such ...
... Scientists of the Max Delbrck Center for Molecular ... Research Center (ECRC) of MDC and Charit in ... of epithelial cells and their molecular repertoire. Dr. ... have identified a transcription factor (grainyhead-like 2, Grhl2), ...
Cached Biology News:Imperial and NTU's new medical school aspires to be global health care role model 2Imperial and NTU's new medical school aspires to be global health care role model 3Imperial and NTU's new medical school aspires to be global health care role model 4A wiki for the biofuels research community 2A wiki for the biofuels research community 3A wiki for the biofuels research community 4New insights into the development of epithelial cells 2
... D-2000, but comes with a shutter (controlled via ... D-2000 Deuterium Light Source produces a powerful, ... versions of the light source are available, providing ... and stable lamp provides peak-to-peak stability of less ...
... CYCLES. An assay kit designed to detect ... PARP is an enzyme implicated in DNA ... is cleaved by caspase-3. Cleavage of PARP ... kDa is a hallmark of apoptosis. Each ...
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Open-slot design ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
Biology Products: